Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | NG-350A |
Synonyms | |
Therapy Description |
Limited information is currently available on NG-350A, a putative anti-CD40-expressing oncolytic vector (Mar, 2019). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NG-350A | NG350A|NG 350A | CD40 Antibody 13 | NG-350A is an oncolytic adenovirus vector expressing a CD40 monoclonal antibody that activates the immune system for an anti-tumor response (PMID: 31890734). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03852511 | Phase I | NG-350A | First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE) | Completed | USA | 0 |